Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)

Next Previous
X
Search
Trial Profile

An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Biomarker; Pharmacodynamics

    • Most Recent Events

    • 13 Sep 2022 Results assessing Immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer, presented at the 47th European Society for Medical Oncology Congress.
    • 18 Jun 2022 Primary results(WJOG9917B) and biomarker analysis(WJOG9917BTR) published in the European Journal of Cancer.
    • 29 Jan 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top